Recursion Pharmaceuticals Inc. Class A (RXRX) Peer Comparison

$3.36

$0.02 (0.60%)

As on 31-Aug-2026 13:37EDT

Market cap

$1,791 Mln

Revenue (TTM)

$55 Mln

P/E Ratio

--

P/B Ratio

2

Div. Yield

0 %

Edit

	Recursion Pharmaceuticals Inc. Class A (RXRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Market cap ($ Mln)	1,791	16,765	16,261	13,492	11,994
Revenue ($ Mln)	55	2,782	1,054	2,436	670
Net Profit ($ Mln)	-518.89	491.50	755.85	860.62	-319.95
Net Margin (%)	-945.92	17.67	71.69	35.33	-47.79
RoE (%)	-50.73	110.09	--	42.98	-71.14
Price to Earnings	--	35.25	19.00	17.40	--
Price-To-Book	2.02	39.29	9.76	7.42	26.87

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Recursion Pharmaceuticals Inc. Class A (RXRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Operating Revenue	54.86	2,782.29	1,054.37	2,435.92	669.50
Cost of Revenue	80.45	1,982.07	103.47	85.67	19.14
Gross Profit	-46.27	760.62	588.53	2,236.43	829.45
Operating Expenses	518.41	216.81	841.45	1,378.74	895.93
Operating Profit (EBIT)	-544.01	583.40	109.45	971.51	-226.44
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-523.47	598.92	101.11	1,035.47	-252.08
Provision for Tax	-4.58	107.42	-654.74	174.84	20.05
Profit after Tax (Net Income)	-518.89	491.50	755.85	860.62	-319.95
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Recursion Pharmaceuticals Inc. Class A (RXRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Shareholder's Funds	915.00	433.86	1,435.90	1,843.76	465.53
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Non-Current Liabilities	177.78	187.89	384.48	288.55	1,362.63
Current Liabilities	119.89	1,435.43	464.70	361.93	283.35
Total Liabilities	1,474.13	1,975.47	1,302.02	2,844.42	1,385.30

Assets ($ Mln)

	Recursion Pharmaceuticals Inc. Class A (RXRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Non-Current Assets	609.21	1,006.90	895.24	1,243.41	440.60
Current Assets	603.46	1,050.29	1,389.84	1,250.82	1,671.41
Total Assets	1,474.13	1,975.47	1,302.02	2,844.42	1,385.30
Total Debt*	61.89	120.10	449.89	165.93	864.07
Net Current Assets	483.58	-385.14	0.00	888.90	1,388.07

Cashflow ($ Mln)

	Recursion Pharmaceuticals Inc. Class A (RXRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Cash From Operating Activities	-371.81	713.22	51.77	884.27	179.55
Cash Flow from Investing Activities	-16.87	-31.14	-8.15	350.44	-129.29
Cash from Financing Activities	521.53	-860.39	34.89	-969.59	74.01
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Recursion Pharmaceuticals Inc. Class A (RXRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
ROCE (%)	-54.82	53.56	-30.01	32.82	-0.17
ROE (%)	-50.73	110.09	163.18	42.98	-71.14
ROA (%)	-37.08	15.64	26.53	29.32	-16.12
EBIT Margin (%)	-953.07	21.13	5.73	31.04	-0.77
Net Margin (%)	-945.92	17.67	71.69	35.33	-47.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Recursion Pharmaceuticals Inc. Class A (RXRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Revenue Growth (%)	-14.88	24.67	114.85	9.23	12.22
EBIT Growth (%)	19.19	18.70	136.39	-3.99	93.17
Net Profit Growth (%)	20.04	17.50	378.76	42.89	-115.58
EPS Growth (%)	41.96	26.84	353.27	50.42	-73.87
Book Value Growth (%)	-21.97	164.02	816.12	-0.70	-13.57

Valuation Ratios

	Recursion Pharmaceuticals Inc. Class A (RXRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Price / Earnings	-3.34	36.06	-59.76	15.79	-2,869.63
Price / Book Value	1.90	35.44	-80.42	5.72	10.04
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-2.66	28.08	-121.54	12.44	25.04
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Recursion Pharmaceuticals Inc. Class A (RXRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debt to Equity	0.01	0.00	0.00	0.00	1.77
Short term debt to equity ratio	0.02	0.00	0.05	0.00	0.09
Current Ratio	5.03	0.73	2.99	3.46	5.90
Quick Ratio	5.03	0.73	2.32	3.38	5.90
Interest Coverage	-347.28	--	1.62	--	-1.72

Operating Efficiency Ratios

	Recursion Pharmaceuticals Inc. Class A (RXRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debtors to sales (%)	26.24	15.88	21.25	13.74	1.28
Asset Turnover	0.04	0.89	0.37	0.83	0.34
Receivable days	180.51	50.42	85.52	43.48	1.50
Inventory Days	--	--	1,056.70	96.17	--
Payable days	59.99	6.26	331.01	147.97	221.81
Cash Conversion Cycle	--	--	811.21	-8.32	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly